Antibody Design

CB-101: An innovative TSAxTAAxCD3 trispecific TCE antibody for solid tumors making undruggable target druggable by widening the therapeutic window

CB-201: An innovative TSAxCD3xCD28 co-stimulatory trispecific TCE antibody for solid tumors making undruggable target druggable by enhancing efficacy without increasing  toxicity

CB-302: An innovative TAA1xTAA2xCD3 trispecific TCE leads to rapid and deep B-cell depletion with well-tolerated safety

CB-401: An innovative TAA1xTAA2xCD3 AND gate trispecific TCE antibody for solid tumors with widening the therapeutic window

CB-501: An innovative masked TAAxCD3xCD28 Contextual gate trispecific TCE antibody for solid tumors with widening the therapeutic window